Kyverna Therapeutics (KYTX) Common Equity (2023 - 2026)

Kyverna Therapeutics' Common Equity history runs 4 years deep, the most recent figure standing at $195.6 million for Q1 2026.

• Quarterly Common Equity fell 12.69% year-over-year to $195.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $195.6 million (down 12.69% YoY) and the FY2025 annual result came in at $232.3 million, down 12.87% from the prior year.
• Common Equity was $195.6 million for Q1 2026 at Kyverna Therapeutics, down from $232.3 million in the prior quarter.
• Across five years, Common Equity topped out at $361.0 million in Q1 2024 and bottomed at -$131.4 million in Q4 2023.
• A 4-year average of $140.5 million and a median of $195.6 million in 2026 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2024 — Common Equity soared 526.64% — and 2025, when it tumbled 49.8%.
• Kyverna Therapeutics' Common Equity stood at -$131.4 million in 2023, then jumped by 302.89% to $266.6 million in 2024, then decreased by 12.87% to $232.3 million in 2025, then dropped by 15.8% to $195.6 million in 2026.
• Business Quant data shows KYTX's Common Equity at $195.6 million in Q1 2026, $232.3 million in Q4 2025, and $151.9 million in Q3 2025.